Hims & Hers Health (NYSE:HIMS) Stock Price Down 7.3% – Time to Sell?

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price dropped 7.3% during mid-day trading on Monday. The company traded as low as $23.91 and last traded at $24.1070. Approximately 5,199,826 shares changed hands during trading, a decline of 76% from the average daily volume of 22,010,988 shares. The stock had previously closed at $26.00.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Revenue rose about 49% year over year to $890.4 million, and international growth provides a potential longer-term expansion opportunity. Hims & Hers: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Neuroscientist and popular health communicator Andrew Huberman joined the board, which could strengthen Hims & Hers’ health expertise and consumer reach. Andrew Huberman appointed director
• Neutral Sentiment: The company plans to offer peptides following eased U.S. restrictions. This could create a growth opportunity, although the product’s regulatory status and associated risks remain important considerations. Hims & Hers to offer peptides
• Negative Sentiment: Quarterly results disappointed: revenue was slightly below estimates, profitability missed expectations, gross margin contracted, and subscribers fell by 100,000 sequentially. The company also cut its 2026 adjusted EBITDA outlook and issued fourth-quarter revenue guidance well below analysts’ expectations. Q3 earnings call highlights
• Negative Sentiment: Five states have joined the FTC’s lawsuit alleging unlawful privacy practices, adding legal, financial and reputational uncertainty. States join FTC privacy suit
• Negative Sentiment: Analysts lowered price targets after the results, including Morgan Stanley, which reduced its target to $25 and maintained an Equal Weight rating. Morgan Stanley lowers HIMS price target

Analyst Upgrades and Downgrades

HIMS has been the subject of several analyst reports. Needham & Company LLC lowered their target price on Hims & Hers Health from $42.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Truist Financial boosted their price target on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a “hold” rating in a report on Monday, August 24th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Finally, Citigroup reduced their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $31.53.

Hims & Hers Health Stock Performance

The firm has a fifty day simple moving average of $28.10 and a 200-day simple moving average of $26.85. The company has a market cap of $4.44 billion, a PE ratio of -22.93 and a beta of 2.53. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 6.65% and a negative return on equity of 9.17%. The firm’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.17 earnings per share. On average, research analysts forecast that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Oluyemi Okupe sold 2,000 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $29.70, for a total transaction of $59,400.00. Following the completion of the sale, the chief financial officer owned 234,527 shares in the company, valued at approximately $6,965,451.90. This represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total transaction of $398,226.53. Following the sale, the chief operating officer owned 456,660 shares of the company’s stock, valued at $12,964,577.40. This trade represents a 2.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 133,905 shares of company stock worth $3,826,977 in the last 90 days. Company insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE grew its position in Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after buying an additional 2,877,550 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Hims & Hers Health in the second quarter valued at about $46,220,000. Bienville Capital Management LLC purchased a new stake in shares of Hims & Hers Health in the second quarter valued at about $27,242,000. Principal Financial Group Inc. increased its stake in shares of Hims & Hers Health by 97.3% during the first quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company’s stock worth $26,620,000 after acquiring an additional 632,282 shares during the period. Finally, Southpoint Capital Advisors LP purchased a new position in Hims & Hers Health during the first quarter worth about $10,380,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.